Vincristine
Highest phase reached
Approved
Drug type
Small molecule
First approval year
1963
- First approval year
- 1963
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Vincristine
- Molecular weight
- 824.97
- Structure (SMILES)
- CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1
- (+)-VINCRISTINE
- 22 oxovincaleukoblastine
- 22-oxovincaleukoblastine
- leucristine
- Leucristine
- leurocristine
- Leurocristine
- oncotcs
- Oncotcs
- tecnocris
- Tecnocris
- vcr
- VCR
- vincaleukoblastine 22 oxo
- Vincaleukoblastine, 22-oxo-
- vincristin
- Vincristin
- vincristina
- Vincristina
- vincristine
- Vincristine
- VINCRISTINE [HSDB]
- vincristine [INN]
- VINCRISTINE [MI]
- VINCRISTINE [VANDF]
And 8 more, listed on the interactive page.
- ATC classification codes
- L01CA02
Sources for recorded values
- CAS registry numbers
- 57-22-7
- ChEMBL ID
- CHEMBL90555
- InChIKey
- OGWKCGZFUXNPDA-XQKSVPLYSA-N
- RxNorm IDs (RxCUI)
- 11202
- FDA ingredient codes (UNII)
- 5J49Q6B70F
- 5978
- 5388993
- Applicant
- LILLY
- Approval date
- 10 Jul 1963
- Application number
- NDA014103
- First in class
- No
- Orphan designation
- No
- Availability
- Prescription only
- Boxed warning
- Yes
- Pharmacology name
- vincristine
- Type
- Natural product
- Drug name stem
- vin-
- Approval recorded by Guide to Pharmacology
- Yes
Administration routes
- Parenteral
Mechanisms of action
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- tubulin beta class I
- Gene symbol
- TUBB
- Protein identifier
- P07437
- Primary target
- Yes
Open Targets mechanisms
- Mechanism
- Tubulin inhibitor
- Action type
- Inhibitor
- Target
- Tubulin
DrugCentral mechanisms
- Action type
- Inhibitor
- Gene symbol
- TUBB|TUBB1|TUBB2A|TUBB2B|TUBB3|TUBB4A|TUBB4B|TUBB6|TUBB8
- Protein identifier
- P07437|Q9H4B7|Q13885|Q9BVA1|Q13509|P04350|P68371|Q9BUF5|Q3ZCM7
- Organism
- Homo sapiens
- Target development level
- Clinical
- Condition
- Leukemia, Biphenotypic, Acute
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000094
- Subject identifier
- D015456
- Condition
- Leukemia, Lymphocytic, Chronic, B-Cell
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000095
- Subject identifier
- D015451
- Condition
- Lymphoma, Follicular
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000096
- Subject identifier
- D008224
- Condition
- Sarcoma, Ewing
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000174
- Subject identifier
- D012512
- Condition
- HIV Infections
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000180
- Subject identifier
- D015658
- Condition
- Hodgkin Disease
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000183
- Subject identifier
- D006689
- Condition
- Leukemia, Biphenotypic, Acute
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000209
- Subject identifier
- D015456
- Condition
- Lymphoma, T-Cell, Peripheral
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000211
- Subject identifier
- D016411
- Condition
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000220
- Subject identifier
- D054198
- Condition
- Leukemia, Myeloid, Acute
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000222
- Subject identifier
- D015470
- Condition
- Rhabdomyosarcoma, Alveolar
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000248
- Subject identifier
- D018232
- Condition
- Immunoblastic Lymphadenopathy
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000255
- Subject identifier
- D007119
- Condition
- Burkitt Lymphoma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000309
- Subject identifier
- D002051
- Condition
- Lymphoma, Large B-Cell, Diffuse
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000403
- Subject identifier
- D016403
- Condition
- Rhabdomyosarcoma, Embryonal
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000437
- Subject identifier
- D018233
- Condition
- Ganglioneuroblastoma
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000502
- Subject identifier
- D018305
- Condition
- Glioblastoma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000519
- Subject identifier
- D005909
- Condition
- Leukemia
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000565
- Subject identifier
- D007938
- Condition
- Lymphoma
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000574
- Subject identifier
- D008223
- Condition
- Neoplasms
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition
- Neuroblastoma
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000621
- Subject identifier
- D009447
- Condition
- Osteosarcoma
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000637
- Subject identifier
- D012516
- Condition
- Sarcoma
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000691
- Subject identifier
- D012509
- Condition
- Small Cell Lung Carcinoma
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000702
- Subject identifier
- D055752
- Condition
- Multiple Myeloma
- Highest recorded phase
- 3
- Condition identifier
- EFO:0001378
- Subject identifier
- D009101
And 41 more, listed on the interactive page.
- Condition identifier
- EFO_0000095
- Condition identifier
- EFO_0000174
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000180
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000183
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000211
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000220
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000403
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000565
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000574
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000616
- Condition identifier
- EFO_0000621
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000658
- Highest recorded phase
- 2
- Condition identifier
- EFO_0001378
- Highest recorded phase
- 3
- Condition identifier
- EFO_0002918
- Highest recorded phase
- 2
- Condition identifier
- EFO_0002939
- Highest recorded phase
- 2
- Condition identifier
- EFO_0004251
- Highest recorded phase
- 1
- Condition identifier
- EFO_0005952
- Highest recorded phase
- 3
- Condition identifier
- EFO_0020985
- Highest recorded phase
- 2
- Condition identifier
- EFO_1000158
- Highest recorded phase
- 3
- Condition identifier
- EFO_1000796
- Highest recorded phase
- 2
- Condition identifier
- EFO_1001365
- Highest recorded phase
- 2
- Condition identifier
- EFO_1001469
- Highest recorded phase
- 3
- Condition identifier
- HP_0001913
- Highest recorded phase
- 1
- Condition identifier
- HP_0002863
- Highest recorded phase
- 2
- Condition identifier
- HP_0009726
- Highest recorded phase
- 3
And 128 more, listed on the interactive page.
Open Targets warnings
- Warning
- Black Box Warning
- Effect
- misuse
- Country
- United States
- Event
- acute myeloid leukaemia
- Reports
- 307
- Reporting signal score
- 541.975
- Event
- anaemia
- Reports
- 1,124
- Reporting signal score
- 415.098
- Event
- b-cell lymphoma recurrent
- Reports
- 120
- Reporting signal score
- 428.555
- Event
- bone marrow failure
- Reports
- 524
- Reporting signal score
- 696.352
- Event
- diffuse large b-cell lymphoma
- Reports
- 282
- Reporting signal score
- 625.227
- Event
- diffuse large b-cell lymphoma recurrent
- Reports
- 324
- Reporting signal score
- 1,111.92
- Event
- diffuse large b-cell lymphoma refractory
- Reports
- 103
- Reporting signal score
- 360.253
- Event
- disease progression
- Reports
- 879
- Reporting signal score
- 692.748
- Event
- dizziness
- Reports
- 139
- Reporting signal score
- 368.699
- Event
- febrile bone marrow aplasia
- Reports
- 524
- Reporting signal score
- 1,476.84
- Event
- febrile neutropenia
- Reports
- 3,240
- Reporting signal score
- 7,147.38
- Event
- haematotoxicity
- Reports
- 486
- Reporting signal score
- 1,042.29
- Event
- hepatitis b
- Reports
- 214
- Reporting signal score
- 386.671
- Event
- hepatitis b reactivation
- Reports
- 175
- Reporting signal score
- 381.681
- Event
- hypofibrinogenaemia
- Reports
- 182
- Reporting signal score
- 567.413
- Event
- infection
- Reports
- 702
- Reporting signal score
- 347.884
- Event
- injection site pain
- Reports
- 3
- Reporting signal score
- 357.917
- Event
- leukopenia
- Reports
- 675
- Reporting signal score
- 588.223
- Event
- mucosal inflammation
- Reports
- 806
- Reporting signal score
- 1,296.31
- Event
- myelodysplastic syndrome
- Reports
- 432
- Reporting signal score
- 776.437
- Event
- neuropathy peripheral
- Reports
- 675
- Reporting signal score
- 385.897
- Event
- neurotoxicity
- Reports
- 318
- Reporting signal score
- 361.886
- Event
- neutropenia
- Reports
- 2,297
- Reporting signal score
- 2,663.7
- Event
- neutropenic sepsis
- Reports
- 217
- Reporting signal score
- 380.32
- Event
- pancytopenia
- Reports
- 730
- Reporting signal score
- 709.678
And 6 more, listed on the interactive page.
- NCT00001209
- NCT00038142
- NCT00568464
- NCT01864109
- NCT02063022
- NCT03359005
- NCT05046314
- NCT04199026
- NCT00001339
- NCT00001689
- NCT00130195
- NCT00131027
- NCT00131053
- NCT00136435
- NCT00137111
- NCT00165178
- NCT00176462
- NCT00184041
- NCT00186875
- NCT00187005
- NCT00187083
- NCT00187161
- NCT00313053
- NCT00313079
- NCT00390793
And 346 more, listed on the interactive page.
- Dose
- 1.4-2 mg/m2 or 0.05 mg/kg (for children 10 kg or less, once a week)
- Route
- Intravenous
- How often
- Weekly
- Hydrogen bond acceptors
- 12
- Hydrogen bond donors
- 3
- Polar surface area
- 171.17
- Calculated partition coefficient (ALogP)
- 3.52
- Calculated partition coefficient (XLogP)
- 2.8
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 2
- Rotatable bonds
- 8
- Heavy atoms
- 60
- Molecular formula
- C46H56N4O10
- Monoisotopic mass
- 824.39964400
- Natural product
- Yes
- Recorded assays
- 3,097
- Active assays
- 704
- Confirmatory
- Other
- Screening
- Summary
- Antineoplastic Agents, Phytogenic
- Tubulin Modulators
These details could not be displayed.
Related records
Trials (542)
- 131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinostat
- A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma
- A Clinical Study of TK216 in Patients With Relapsed or Refractory Ewing's Sarcoma
- A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)
- A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)
- A Dose Study of Doxil in a Dose Dense, 14 Day CDOP/Rituximab Regimen for Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma (NHL)> 60 Years or With Compromised Cardiac Status.
- A Multi-institutional Study for Treatment of Children With Newly Diagnosed Hepatoblastoma Using a Modified PHITT Strategy
- A Multicenter, Prospective, Open-Label, Randomized Controlled Clinical Study of Orelabrutinib Combined With Obinutuzumab and Lenalidomide Versus Obinutuzumab Plus Chemotherapy for Treatment-Naive Follicular Lymphoma
- A Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL)
- A Novel "Pediatric-Inspired" Regimen With Reduced Myelosuppressive Drugs for Adults (Aged 18-60) With Newly Diagnosed Ph Negative Acute Lymphoblastic Leukemia
- A Pharmacokinetic and Pharmacodynamic Study of Vincristine in Children With Leukemia
- A Pharmacokinetic Study of Actinomycin-D and Vincristine in Children With Cancer
- A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell Neoplasms
- A Phase 1, Open-label Trial of Oral Azacitidine (CC-486) Plus RCHOP in Subjects With Large B-Cell Lymphoma or Follicular Lymphoma or Transformed Lymphoma
- A Phase I Dose Finding Study in Children With Solid Tumors Recurrent or Refractory to Standard Therapy
- A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas
- A Phase I/II Study of Lenalidomide and Obinutuzumab With CHOP for Diffuse Large B Cell Lymphoma
- A Phase I/II Trial of VR-CHOP in Lymphoma Patients
- A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma
- A Phase II Study of Rituximab Combined With CHOP in T-cell Angio-immunoblastic Lymphoma
Approved for (1)
- Neoplasm
In development for (64)
- Acute leukemia of ambiguous lineage Phase 2
- Acute lymphoblastic leukemia Phase 3
- Acute myeloid leukemia Phase 3
- Adrenal cortex carcinoma Phase 2
- Adult T-cell leukemia/lymphoma Phase 3
- Alveolar rhabdomyosarcoma Phase 3
- Anaplastic astrocytoma Phase 2
- Anaplastic ependymoma Phase 3
- Anaplastic large cell lymphoma Phase 2
- Angioimmunoblastic T-cell lymphoma Phase 2
- Autoimmune thrombocytopenic purpura Phase 2
- B-cell acute lymphoblastic leukemia Phase 2
- B-cell chronic lymphocytic leukemia Phase 3
- B-cell non-Hodgkin lymphoma Phase 1
- Blast phase chronic myelogenous leukemia, BCR-ABL1 positive Phase 2
- Brain cancer Phase 3
- Brain neoplasm Phase 3
- Burkitt lymphoma Phase 2
- Castleman disease Phase 1
- CD4+/CD56+ hematodermic neoplasm Phase 2
Targets (15)
- TUBA1A Tubulin inhibitor
- TUBA1B Tubulin inhibitor
- TUBA1C Tubulin inhibitor
- TUBA3C Tubulin inhibitor
- TUBA3E Tubulin inhibitor
- TUBA4A Tubulin inhibitor
- TUBB Tubulin inhibitor
- TUBB1 Tubulin inhibitor
- TUBB2A Tubulin inhibitor
- TUBB2B Tubulin inhibitor
- TUBB3 Tubulin inhibitor
- TUBB4A Tubulin inhibitor
- TUBB4B Tubulin inhibitor
- TUBB6 Tubulin inhibitor
- TUBB8 Tubulin inhibitor